Experienced in Chronic B-Cell Leukemia (CBCL)

Martin Gramatzki

Kiel, SH, DE 
Experienced in Chronic B-Cell Leukemia (CBCL)
Kiel, SH, DE 
OverviewLocationsClinical Research

Overview

Martin Gramatzki practices in Kiel, Germany. Mr. Gramatzki is rated as an Experienced expert by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Multiple Myeloma, Plasmacytoma, Leukemia, Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Transplant.

His clinical research consists of co-authoring 77 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Chronic B-Cell Leukemia (CBCL).

Gender
Male

Locations

Kiel, SH, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance - A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance - A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV
Enrollment Status: Unknown
Publish Date: April 27, 2023
Intervention Type: Biological, Drug
Study Drugs: Lenalidomide, Bortezomib, Autologous Stem Cell Transplant, Aallogeneic Stem Cell Transplant
Study Phase: Phase 3

77 Total Publications

Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.
Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.
Journal: Frontiers in immunology
Published: May 23, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Gramatzki's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile